

Features of FerriScan[®]

- FerriScan[®] is used to non-invasively measure liver iron concentration (LIC) from specially acquired MRI images;
- FerriScan[®] has been used to non-invasively measure LICs in over 50,000 patients;
- FerriScan[®] measures across the full range of iron loading seen in clinical practice. This range is larger than that which is achievable using any other published MRI-based method;
- FerriScan[®] has been calibrated against liver biopsy to measure LICs from 0.3 to 42.7 mg Fe/g dry tissue in a trial of 105 subjects with hereditary haemochromatosis and thalassemia disorders using 5 different MRI scanners.
- FerriScan[®] is not influenced by the presence of liver fat or fibrosis;
- FerriScan[®] has been validated on GE, Philips and Siemens scanners;
- FerriScan[®] has regulatory clearances from the FDA, TGA, and European CE mark;
- FerriScan[®] has been independently validated by third parties;
- FerriScan[®] has been used and is being used in many multinational clinical trials by pharmaceutical and therapeutic companies for the quantification of LIC in trial subjects;
- Every part of the FerriScan[®] process is standardised globally, from image acquisition to analysis and report generation. All data analysis is performed under stringent quality controlled conditions in an ISO certified core laboratory. FerriScan[®] uses a strictly standardised data acquisition and data analysis in order to assure correct calibration across all makes and models of MRI scanners.
- FerriScan[®] also has FDA clearance as MR companion diagnostic for use with deferasirox;


Advantages of FerriScan[®] over serum ferritin (SF)

- Other factors present in patients with iron overload such as infection, inflammation, fever, cancer, metabolic disease, or liver damage may result in significant elevation of serum ferritin concentrations in the absence of iron overload;
- SF has poor accuracy for measuring body iron loading in patients with thalassaemia major¹;
- SF levels in patients with thalassaemia intermedia are significantly lower than in patients with thalassaemia major despite them having comparable Liver Iron Concentration (LIC) levels (as determined by biopsy), suggesting that SF significantly underestimates iron loading in patients with thalassaemia Intermedia²;
- Increased serum ferritin concentrations may indicate iron overload, but are not a quantitative measure of iron burden. Additionally, once SF becomes saturated, there is poor correlation between SF and iron levels;
- SF is an imprecise and potentially misleading parameter on which to base clinical management decision in patients with sickle cell disease (SCD)³;
- The relationship between total body iron stores and SF in patients with hereditary haemochromatosis is very weak^{4, 5};
- SF has significant limitations in assessment of iron burden in children with SCD, and liver iron assessment therefore is necessary for optimal management.

What are the limitations of Liver T2* (MRI)

- There are a number of liver T2* techniques and these are not standardised. Non standardisation means that it is very difficult to compare results. See Graph 1 below;
- The liver T2* techniques are not regulatory cleared;
- As a patient's LIC starts to climb, the liver T2* techniques become more unreliable and eventually fail at higher iron levels. This can occur from 15 mg/g dry weight (depending on method of acquisition and analysis);
- The liver T2* methods do not report across the full range of iron loading seen in clinical practice. (Published liver T2* methods measured LICs up to 23.6, 27.67 and 32.98 mg/g dry tissue, respectively.)
- The liver T2* techniques can be influenced by the presence of liver fat and fibrosis;
- A review of the literature shows that, unlike FerriScan® R2-MRI, liver T2* methods generate data that are scanner and method dependent and hence are not sufficiently standardised to enable reliable liver iron concentration measurements using calibration curves published from other centres;
- Liver T2* to LIC conversion is dependent on a number of factors including various scanning profiles, various methods of analysis, and which calibration curve is used. The variance in several T2* techniques can be seen in the tables below. For the purposes of comparison, the LIC result derived from a calculated liver T2* value of 2.5ms will vary widely depending on which calibration curve has been used for conversion (see red line on Graph 1 below).

Number on Graph	Published reference	LIC (mg/g dw)
1	Anderson et al, 2001	5.4
2	Wood et al, 2005	10.4
3	Hankins et al, 2009	10.7
4	Garbowski et al, 2009	12.7
5	Chan et al, 2010	15.4
6	Christoforidis et al, 2009	26.4



Graph 1 showing various Liver T2* calibration conversions to LIC.

Advantages of FerriScan® over liver biopsy

- Non-invasive, painless, no risk of bleeding or infection;
- Provides information about the distribution of iron in the liver;
- The size of the biopsy specimen only represents 1/50,000th of the total mass of the liver, therefore the sampling error is potentially large - the location where the biopsy is taken from will affect the result, and may not be representative of the entire liver.
- FerriScan® measures iron in a volume of liver that is thousands of times greater than liver biopsy and therefore has a much smaller sampling error;

References

1. Brittenham, G et al. Am J Hematol. 1993;42 (1):81-5.
2. Taher, A. et al. Haematologica, 2008. 93. 1584-6.
3. Kwiatkowski, J. et al Hematol Oncol Clin North Am, 2004. 18. 1355-77, ix.
4. Olynyk, J. et al Am J Gastroenterol, 1998. 93. 346-50
5. Gordeuk, V. Am J Hematol, 2008. 83. 618-26.
6. Anderson et al (2001) Eur Heart J, 22:2171-2179.
7. Wood et al (2005) Blood, 106: 1460-1465.
8. Garbowski et al (2009) ASH Annual Meeting Abstracts, 114(22): 2004.
9. St Pierre et al (2005) Blood; 105:855-861.
10. St Pierre et al (2013) Magn Reson Med doi: 10.1002/mrm.24854